Haemophilia care in children - Benefits of early prophylaxis for inhibitor prevention

Haemophilia

Volumn 15, Issue SUPPL. 1, 2009, Pages 8-14

  Mancuso, M E ^a   Graca, L ^b   Auerswald, G ^c   Santagostino, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c Prof Hess Kinderklinik   (Germany)

Author keywords

Children; Haemophilia A; Immune tolerance induction; Inhibitors; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ARTHROPATHY; BLEEDING; CELL ACTIVATION; CHILD; CHILD CARE; CONFERENCE PAPER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; EARLY INTERVENTION; EUROPE; GENE MUTATION; GENETIC RISK; HEMARTHROSIS; HEMOPHILIA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE; VASCULAR ACCESS;

BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; INFANT, NEWBORN;

EID: 62149132517     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01947.x     Document Type: Conference Paper

References (38)

1. Lafeber FP, Miossec P, Valentino LA. Physiopathology of haemophilic arthropathy. Haemophilia 2008; 14 (Suppl. 4): 3-9.
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
3. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
5. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
6. Astermark J, Oldenburg J, Escobar M, White GC II, Berntorp E. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005; 90: 924-31.
7. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
8. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
9. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
10. Development of factor VIII antibody in haemophilic monozygotic twins. European Study Group of Factor VIII Antibody. Scand J Haematol 1979; 23: 64-8.
11. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-3.
12. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-9.
13. Morado M, Villar A, Jimenez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: Experience in one centre. Haemophilia 2005; 11: 79-83.
14. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
15. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
16. Agua-Doce A, Graca L. Induction of dominant tolerance using monoclonal antibodies. Methods Mol Biol 2007; 380: 405-29.
17. Graca L, Chen TC, Le Moine A, Cobbold SP, Howie D, Waldmann H. Dominant tolerance: Activation thresholds for peripheral generation of regulatory T cells. Trends Immunol 2005; 26: 130-5.
18. Graca L, Le Moine A, Cobbold SP, Waldmann H. Antibody-induced transplantation tolerance: The role of dominant regulation. Immunol Res 2003; 28: 181-91.
19. Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303-7.
20. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-302.
21. Graca L, Honey K, Adams E, Cobbold SP, Waldmann H. Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J Immunol 2000; 165: 4783-6.
22. Oliveira V, Agua-Doce A, Duarte J, Soares MP, Graca L. Regulatory T cell maintenance of dominant tolerance: Induction of tissue self-defense? Transpl Immunol 2006; 17: 7-10.
23. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002; 195: 1641-6.
24. Nilsson IM. The management of hemophilia patients with inhibitors. Transfus Med Rev 1992; 6: 285-93.
25. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
26. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-5.
27. Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999; 5: 286-91.
28. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
29. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
30. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
31. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
32. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001; 7: 99-102.
33. Petrini P. How to start prophylaxis. Haemophilia 2003; 9 (Suppl. 1): 83-5 (Discussion 6-7).
34. van den Berg HM, Fischer K, Mauser-Bunschoten EP et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001; 112: 561-5.
35. Feldman BM, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
36. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 2004; 10: 134-46.
37. Mancuso ME, Mannucci PM, Sartori A, Agliardi A, Santagostino E. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. Br J Haematol 2008; 141: 689-95.
38. Santagostino E, Mancuso ME, Gringeri A, Siboni S, Mannucci PM. Low-rate of complications after a long-term use of arteriovenous fistula (AVF) in hemophilic children. Haemophilia 2008; 14 (Suppl. 2): 99 (Abstract 16 FP 05).